Accelerate.EUAdvancing cancer treatment is at the heart of Accelerate. EU.
By ensuring access to #211At across Europe and aligning research efforts, we’re moving towards more effective, targeted therapies. This is a key step in improving outcomes for people living with cancer.
Accelerate. EU will explore co-clinical approaches, where clinical studies run in parallel with preclinical studies, enhancing the ability to identify patients who are most likely to benefit from 211At therapy.
By ensuring access to #211At across Europe and aligning research efforts, we’re moving towards more effective, targeted therapies. This is a key step in improving outcomes for people living with cancer.
Accelerate. EU will explore co-clinical approaches, where clinical studies run in parallel with preclinical studies, enhancing the ability to identify patients who are most likely to benefit from 211At therapy.
